Can regenerative medicine save Big Pharma’s business model from the patent cliff?

Author： Denoon Alexander Vollebregt Erik

ISSN： 1746-0751

Source： Regenerative Medicine, Vol.5, Iss.5, 2010-09, pp. : 687-690

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Patent Survey on Current Applications of Supercritical Fluid Technology in Regenerative Medicine

Recent Patents on Nanomedicine, Vol. 5, Iss. 1, 2015-04 ,pp. : 48-58

Bentham Science Publishers

Access to resources Recommend Favorite

Regenerative medicine

By Minger Stephen L

Regenerative Medicine, Vol. 1, Iss. 1, 2006-01 ,pp. : 1-2

Future Medicine

Access to resources Recommend Favorite

The dominance of big pharma: power

By Edgar Andrew

Medicine, Health Care and Philosophy, Vol. 16, Iss. 2, 2013-05 ,pp. : 295-304

Springer Publishing Company

Access to resources Recommend Favorite

Big pharma — paper tiger

By Fitzpatrick Mike

British Journal of General Practice, Vol. 56, Iss. 525, 2006-04 ,pp. : 309-309

Royal College of General Practitioners

Access to resources Recommend Favorite

Associating Paracrine Communication to Regenerative Medicine: Search Strategies & Major Trends in Scientific and Patent Production

Recent Patents on Regenerative Medicine, Vol. 3, Iss. 1, 2013-01 ,pp. : 74-90

Bentham Science Publishers

Access to resources Recommend Favorite